A perspective on surrogate endpoints in controlled clinical trials

DOI10.1191/0962280204SM362RAzbMATH Open1121.62639OpenAlexW2340418739WikidataQ35805910 ScholiaQ35805910MaRDI QIDQ5424596FDOQ5424596

Authors: Geert Molenberghs, Tomasz Burzykowski, Ariel Alonso, Marc Buyse 

Publication date: 5 November 2007

Published in: Statistical Methods in Medical Research (Search for Journal in Brave)

Full work available at URL: http://hdl.handle.net/1942/673

Recommendations

• Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
• The evaluation of surrogate endpoints.
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
• The validation of surrogate endpoints in meta-analyses of randomized experiments
• Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cited In (13)

• Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
• Center-within-trial versus trial-level evaluation of surrogate endpoints
• Placebos that harm: sham surgery controls in clinical trials
• Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
• Information Recovery in a Study With Surrogate Endpoints
• Statistical Methods for Clinical Studies in the Presence of Surrogate End Points
• Incomplete multiresponse designs and surrogate endpoints in clinical trials
• Patient reported outcomes as endpoints in medical research
• The Evaluation of Multiple Surrogate Endpoints
• Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
• Dynamic optimal strategy for monitoring disease recurrence
• Bias reduction using surrogate endpoints as auxiliary variables

This page was built for publication: A perspective on surrogate endpoints in controlled clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5424596)